Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Intermune IncfiledCriticalArray Biopharma Inc
Priority to CU20090188ApriorityCriticalpatent/CU20090188A7/en
Publication of CU20090188A7publicationCriticalpatent/CU20090188A7/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Compuestos de fórmula I, y también composiciones, incluyendo composiciones farmacéuticas, que comprenden uno de dichos compuestos. En las realizaciones se proporcionan compuestos de fórmula general II, y también composiciones, incluyendo composiciones farmacéuticas, que comprenden uno de dichos compuestos. Además, en las realizaciones se proporcionan métodos de tratamiento, incluyendo métodos para tratar una infección de virus de hepatitis C, y métodos para tratar la fibrosis hepática, donde los métodos generalmente comprenden administrarle a un individuo que lo necesita una cantidad eficaz de uno de dichos compuestos o composiciones.Compounds of formula I, and also compositions, including pharmaceutical compositions, comprising one of said compounds. Compounds of general formula II, and also compositions, including pharmaceutical compositions, comprising one of said compounds are provided in the embodiments. In addition, the methods provide treatment methods, including methods for treating a hepatitis C virus infection, and methods for treating liver fibrosis, where the methods generally comprise administering to an individual in need an effective amount of one of said compounds or compositions
CU20090188A2009-11-102009-11-10
NEW INHIBITING PEPTIDES OF HEPATITIS C VIRUS REPLICATION
CU20090188A7
(en)
Thiophene-2-carboxylic acid derivative compounds; flaviviridae virus inhibitors; pharmaceutical composition comprising them; Useful in the treatment of hepatitis c. pct national phase
Benzimidazole-imidazole derivative compounds, hepatitis c virus (hcv) inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; use in the prevention or treatment of hcv infection.
"4-aryl-n- [3- (sulfonimidoyl) phenyl] -1,3,5-triazin-2-amine substituted compounds, cdk inhibitors; intermediary compounds, composition and pharmaceutical combination comprising them; and its use in the treatment of hyperproliferative, infectious diseases induced by viruses and / or cardiovascular diseases ”. pct